{"id":"mevac-a-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine targets antigens related to the mevalonate metabolic pathway, which is often dysregulated in cancer cells. By inducing cellular and humoral immune responses against these pathway-associated targets, the vaccine aims to enable the immune system to recognize and eliminate cancer cells. This approach leverages the metabolic vulnerabilities of malignant cells.","oneSentence":"Mevac-A is a therapeutic vaccine designed to stimulate immune responses against mevalonate pathway-associated antigens to treat cancer.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:49:59.021Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific indication under investigation in phase 3)"}]},"trialDetails":[{"nctId":"NCT06298708","phase":"PHASE3","title":"Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents","status":"COMPLETED","sponsor":"Chiang Mai University","startDate":"2024-04-27","conditions":"HAV, Hepatitis A, Hep A","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Mevac-A vaccine","genericName":"Mevac-A vaccine","companyName":"Chiang Mai University","companyId":"chiang-mai-university","modality":"Biologic","firstApprovalDate":"","aiSummary":"Mevac-A is a therapeutic vaccine designed to stimulate immune responses against mevalonate pathway-associated antigens to treat cancer. Used for Cancer (specific indication under investigation in phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}